We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Platelet-to-Lymphocyte Ratio and Use of NSAIDs During the Perioperative Period as Prognostic Indicators in Patients With NSCLC Undergoing Surgery.
- Authors
Lee, Brenda M.; Rodríguez, Andrea; Mena, Gabriel; Gottumukkala, Vijaya; Mehran, Reza J.; Rice, David C.; Lei Feng; Jun Yu; Cata, Juan P.; Rodriguez, Andrea; Feng, Lei; Yu, Jun
- Abstract
<bold>Background: </bold>Hematological biomarkers of inflammation such as the neutrophil-to-lymphocytic rate have been reported as predictors of survival in a variety of cancers. The aim of the present study was to investigate the prognostic value of the perioperative platelet-to-lymphocyte ratio in patients with non-small-cell lung cancer (NSCLC) and to elucidate the effects of the perioperative use of nonsteroidal anti-inflammatory drugs (NSAIDs) on tumor recurrence and survival in patients undergoing surgical resection for NSCLC.<bold>Methods: </bold>This retrospective study included data from 1,637 patients who underwent surgical resection for stage I, II, or III NSCLC. Perioperative data and tumor-related variables were included. Univariate and multivariable Cox proportional hazard ratio (HR) models were used to evaluate the association between perioperative platelet-to-lymphocyte ratio and NSAID use on recurrence-free survival (RFS) and overall survival (OS).<bold>Results: </bold>Multivariate analysis showed that a preoperative platelet-to-lymphocyte ratio of at least 180 was associated with reduced rates of RFS (HR = 1.22; 95% confidence interval [CI], 1.03-1.45; P = .019) and OS (HR = 1.33; 95% CI, 1.10-1.62; P = .004). Perioperative use of NSAIDs showed no statistically significant changes in RFS and OS rates (P = .72 and P = .44, respectively).<bold>Conclusions: </bold>A higher preoperative inflammatory status is associated with decreased rates of RFS and OS in patients with NSCLC undergoing curative surgery. Perioperative use of NSAIDs was not found to be an independent predictor of survival.
- Subjects
BLOOD platelets; LUNG cancer; LUNG tumors; LYMPHOCYTES; NONSTEROIDAL anti-inflammatory agents; PROGNOSIS; RESEARCH funding; SURGICAL therapeutics; RETROSPECTIVE studies
- Publication
Cancer Control: Journal of the Moffitt Cancer Center, 2016, Vol 23, Issue 3, p284
- ISSN
1073-2748
- Publication type
journal article
- DOI
10.1177/107327481602300312